Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $177.50 short put and a strike $172.50 long put offers a potential 50.15% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $177.50 by expiration. The full premium credit of $1.67 would be kept by the premium seller. The risk of $3.33 would be incurred if the stock dropped below the $172.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 72.65 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Why Amgen Expects EPS to Rise in 2018
Wed, 30 May 2018 21:30:02 +0000
Amgen (AMGN) has projected its non-GAAP EPS for 2018 at $12.60–$13.70. That assumes a non-GAAP tax rate guidance of 13.5%–14.5%, which is lower than the previously projected range of 14%–15%. That can be attributed to the realization of certain favorable one-time events associated with the Tax Cuts and Jobs Act passed in 2017. It also expects to witness capital expenditures of $750 million in 2018.
Why Amgen Revised Its Revenue Guidance for 2018
Wed, 30 May 2018 20:00:02 +0000
In its first-quarter conference call, Amgen (AMGN) revised its revenue guidance from $21.8 billion–$22.8 billion to $21.9 billion–$22.8 billion. Amgen saw strong demand trends in the first quarter for Parsabiv, its other calcimimetic drug that has been launched in the United States as well as international markets. Its peers Biogen (BIIB), Celgene (CELG), and Gilead Sciences (GILD) are expected to report revenues of $12.9 billion, $14.9 billion, and $20.8 billion, respectively, in 2018.
Amgen Foundation And Harvard Team Up To Offer Free Online Science Education Platform
Wed, 30 May 2018 20:00:00 +0000
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., May 30, 2018 /PRNewswire/ — The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process. “There are many millions of students who, as a result of economic or geographic limitations, simply do not have access to one of the most central aspects of being a scientist, which is working in a laboratory,” said Professor Robert Lue, principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard.
Analyst Recommendations for Amgen and Its Peers in May
Wed, 30 May 2018 18:27:49 +0000
In the first quarter, Amgen (AMGN) reported total revenues of $5.6 billion, which is a YoY (year-over-year) rise of 2%. It also reported total product sales of $5.3 billion, a YoY rise of 3% and a sequential decline of 4%. Sales were boosted by a double-digit rise in unit sales for all of Amgen’s recently launched products, including Xgeva, Prolia, Repatha, and Kyprolis.
Biotech ETFs Are the Best Way to Play the Recovering Sector
Wed, 30 May 2018 15:43:14 +0000
The summer of 2015 marked the end of the glory years in the biotechnology sector. The biotech valuation correction that lasted over two years may be coming to an end. Some well-known, large-cap names — such as AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) — are currently trading at forward P/E multiples in the 10+ range.
Also on Market Tamer…
Follow Us on Facebook